Seeds to trees

Novo A/S using strong cash flow to invest in mature companies like Xellia

Flush with cash from its existing holdings and not seeing enough worthwhile venture deals to spend it on, Novo A/S has decided to expand its growth equity investments in mature companies. After a proof-of-principle deal done last year showed the approach could provide strong growth, the Danish holding company struck a second deal last month with the acquisition of generics company Xellia Pharmaceuticals A/S.

Xellia develops and manufactures APIs and finished dosage forms of antibacterials and antifungals. Novo agreed to acquire the company from private equity firm 3i Group for about $700 million.

Ulrik Spork, managing partner of Novo Growth Equity fund, said

Read the full 1013 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE